AI Therapeutics has begun dosing in a clinical trial testing inhaled LAM-001, a potential disease-modifying therapy for pulmonary arterial hypertension (PAH). The 24-week, open-label Phase 2 study (NCT05798923) is recruiting 15 adults at Brigham and Women’s Hospital in Boston, Massachusetts. All participants should have advanced PAH…
News
Psychological counseling and therapy are among the interventions that may help adults with pulmonary hypertension (PH) manage depression and anxiety, a review paper reports. Data in this area are limited, however, and the review highlighted a need for more research into how best to support the mental health…
Scientists have identified gene, protein, and signaling pathway alterations in the livers of people with portopulmonary hypertension (PoPH) — a form of pulmonary arterial hypertension (PAH) usually associated with liver disease — that could reflect underlying mechanisms of the rare disorder. Compared with liver disease patients without PoPH, those…
Engaging in inspiratory muscle training for eight weeks may help people with pulmonary hypertension (PH) strengthen their respiratory (breathing) muscles and gain exercise capacity, a study suggests. This is important because inspiratory (breathing in) muscle training may offer a non-invasive approach to improve the quality of life and overall…
Echocardiography, a noninvasive imaging method to examine heart structure and function, can be useful in making a preliminary diagnosis of pulmonary hypertension and in determining its likely course, according to a review study. “In future, it is important to use multiple echocardiographic parameters for detection and predicting the prognosis…
The PAH Initiative‘s PAH Today national broadcast series returns in September and November with presentations from a pulmonary arterial hypertension (PAH) specialist for adult patients and their caregivers on managing the disease. This year’s series, which offers insights and perspectives on coping with PAH, includes two programs covering…
Among patients undergoing surgery for a heart valve disease, the presence of pulmonary hypertension (PH) was associated with a worse prognosis, particularly for patients with high pulmonary vascular resistance (PVR). PVR is an an indicator of resistance to blood flow in the pulmonary arteries sending blood from the heart…
About one-quarter of the pulmonary arterial hypertension (PAH) patients in a small study showed cognitive deficits, typically mild impairments in executive function and memory. Problems in abilities like executive function — a set of skills that include thinking, self control, and readily accessible memory that’s part of everyday life…
Inhaled nitric oxide (iNO) therapy reduces the risk of death in preterm infants with severe hypoxemic respiratory failure (HRF) — low oxygen in the blood — and suspected or confirmed pulmonary hypertension (PH), a study shows. “The findings provide evidence supporting the prognostic value of oxygenation response and support…
The risk of mortality is nine times greater for people who have signs of pulmonary hypertension (PH) on an echocardiogram when they get COVID-19, than people without these signs, a study finds. The study, “Pulmonary hypertension predicts higher mortality in patients admitted with severe COVID-19 infection,” was published…
Certain proteins implicated in the immune response and inflammation showed a potential to serve as blood biomarkers of pulmonary arterial hypertension (PAH) in a recent study. A possible diagnostic biomarker was seen in the TNF‐related apoptosis‐inducing ligand (TRAIL) protein. It demonstrated an ability to distinguish PAH patients not only…
Scientists in India have developed derivatives of bosentan — the active ingredient in Tracleer — that were able to ease signs of pulmonary arterial hypertension (PAH) in a rat model. In addition to lowering blood pressure and restoring more normal heart and lung architecture, the molecules lowered biomarkers…
